https://medicine.ouhsc.edu/Academic-Departments Parent Page: Academic Departments id: 22555 Active Page: Facultyid:23541

Faculty

Internal Medicine

Ralph T. Guild III, MD

Professor of Medicine


COMD 7400
800 Stanton L Young Blvd
Oklahoma City, OK

 

405-270-0501 x5313 (VA Office)

Ralph-Guild@ouhsc.edu


Dr. Guild is a board-certified gastroenterologist and a professor at the OU College of Medicine. Dr. Guild sees patients at the Oklahoma City Veterans Affairs Medical Center and at OU Physicians. He has a special interest in diagnosing and treating patients with Gastroesophageal Reflux Disease and Peptic Ulcer Disease. Guild completed a fellowship and residency at the University of Florida after earning his medical degree at the OU College of Medicine.​


Academic Section(s):

Digestive Diseases


Education:

University of Oklahoma College of Medicine, Oklahoma City, OK
MD (1974)
 


Board Certification(s):

American Board of Internal Medicine
Internal Medicine (1977, non-expiring)

American Board of Internal Medicine
Gastroenterology (1981, non-expiring)

 


Residency:

University of Florida, Gainesville, FL
Internal Medicine (1977)


Fellowship:

University of Florida, Gainesville, FL
Gastroenterology (1981)


Clinical/Research Interests:

  • Colon cancer
  • Reflux disease
  • Diarrhea
  • Constipation


Funding:

Clinical Trials
 

“A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation”

           Co-Principal Investigator

           Funding organization: Synergy Pharmaceuticals

           Starting date: October 2014

 

 “A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn’s Disease”

      Co-Principal Investigator

      Funding Organization: Salix Pharmaceuticals

      Starting Date: April 2015

 

“A Multi-Center, Randomized, Open Label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer® (Ferric Carboxymaltose) vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron Deficiency Anemia(IDA) secondary to Inflammatory Bowel Disease(IBD) or Gastric Bypass.”

Co-Principal Investigator

Funding Organization: Luitpold Pharmaceuticals, Inc.

Starting Date: April 2015

 

“An Open-Label , Long-Term Safety and Tolerability Study of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)”

Co-Principal Investigator

Funding Organization: Synergy Pharmaceuticals

Starting Date: October 2015


Select Honors & Accomplishments:

  • Castle Connolly Medical Ltd. "Top Doctors", 2016-2018
  • Fellow, American College of Gastroenterology


Select Publications:

Research Networking Profile